FDA approves new form of Lamisil
WASHINGTON Novartis has received approval from the Food and Drug Administration to market a new oral form of Lamisil, which is used to treat people age 4 years and older with ringworm of the scalp.
Three to four million people in the U.S. who suffer the condition are under the age of 10, according to Novartis. The new Lamisil Oral Granules are meant to be taken once daily for six weeks.
The granules are expected to hit the markets starting in January.